Aquatic Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Aquatic Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.63M	Buy	+362,895	New	+$3.28M	0.12%	211
2025 Q4	–	Sell	-63,242	Closed	-$480K	–	1412
2025 Q3	$480K	Sell	63,242 -144,532	-70%	-$1.2M	0.01%	880
2025 Q2	$1.86M	Buy	+207,774	New	+$1.93M	0.04%	490
2025 Q1	–	Sell	-55,890	Closed	-$420K	–	1271
2024 Q4	$420K	Sell	55,890 -80,210	-59%	-$609K	0.01%	758
2024 Q3	$1.03M	Buy	136,100 +122,400	+893%	+$930K	0.03%	496
2024 Q2	$84.7K	Buy	13,700 +10,400	+315%	+$57.4K	﹤0.01%	927
2024 Q1	$16.8K	Sell	3,300 -200	-6%	-$1.13K	﹤0.01%	1113
2023 Q4	$21K	Sell	3,500 -61,100	-95%	-$354K	﹤0.01%	1213
2023 Q3	$457K	Buy	64,600 +35,800	+124%	+$257K	0.02%	499
2023 Q2	$203K	Buy	28,800 +7,800	+37%	+$62.6K	0.01%	661
2023 Q1	$175K	Sell	21,000 -7,600	-27%	-$73.2K	0.01%	622
2022 Q4	$328K	Buy	28,600 +22,000	+333%	+$274K	0.02%	614
2022 Q3	$83K	Buy	6,600 +5,600	+560%	+$72.1K	0.01%	801
2022 Q2	$11K	Buy	+1,000	New	+$10.3K	﹤0.01%	951

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jupiter Topco New York $245B AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Aquatic Capital Management's BCRX Position: Q2 2026 in Review

Aquatic Capital Management opened a new position in BioCryst Pharmaceuticals (BCRX) in Q2 2026: 362,895 shares worth $3.63M. The stake represents 0.12% of the portfolio and ranks #211 among its holdings. This is a return to the name: Aquatic Capital Management previously reported a position in BCRX as recently as Q3 2025.

Aquatic Capital Management first reported a position in BCRX in Q2 2022 and has held it in 14 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

Aquatic Capital Management held 362,895 shares of BioCryst Pharmaceuticals worth $3.63M as of Q2 2026.
BioCryst Pharmaceuticals was a new Aquatic Capital Management position in Q2 2026.
BioCryst Pharmaceuticals made up 0.12% of Aquatic Capital Management's portfolio in Q2 2026, its #211 holding.
Aquatic Capital Management first reported a position in BioCryst Pharmaceuticals in Q2 2022 and has held it in 14 quarters since.
318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Aquatic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.